# Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia

> **NCT02293993** · PHASE1 · COMPLETED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 21 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** SGI-110

## Key facts

- **NCT ID:** NCT02293993
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-07
- **Primary completion:** 2017-06-14
- **Final completion:** 2019-05-31
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2021-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02293993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02293993, "Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02293993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*